seed
Stage
About
Ocythera develops selective small molecule inhibitors targeting the retinoic acid pathway to treat rare genetic bone diseases such as Fibrodysplasia Ossificans Progressiva (FOP) and Hereditary Multiple Osteochondromas (MO).
Explore Ocythera's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.